Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM, Morel D, Eychenne T, Colmet-Daage L, Bajrami I, Dorvault N, Garrido M, Meisenberg C, Lamb A, Ngo C, Hopkins SR, Roumeliotis TI, Jouny S, Hénon C, Kawai-Kawachi A, Astier C, Konde A, Del Nery E, Massard C, Pettitt SJ, Margueron R, Choudhary JS, Almouzni G, Soria JC, Deutsch E, Downs JA, Lord CJ, Postel-Vinay S. Chabanon RM, et al. Among authors: henon c. Cancer Res. 2021 Jun 1;81(11):2888-2902. doi: 10.1158/0008-5472.CAN-21-0628. Cancer Res. 2021. PMID: 33888468
Patient-reported tolerability of adverse events in phase 1 trials.
Henon C, Lissa D, Paoletti X, Thibault C, Le Tourneau C, Lanoy E, Hollebecque A, Massard C, Soria JC, Postel-Vinay S. Henon C, et al. ESMO Open. 2017 Jun 23;2(2):e000148. doi: 10.1136/esmoopen-2016-000148. eCollection 2017. ESMO Open. 2017. PMID: 28761740 Free PMC article.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S. Chabanon RM, et al. Among authors: henon c. J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11. J Clin Invest. 2019. PMID: 30589644 Free PMC article.
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study.
Watson S, Verret B, Ropert S, Adam J, Bahleda R, Briand S, Cavalcanti A, Chamseddine AN, Court C, Fadel E, Faron M, Haddag-Miliani L, Henon C, Pechoux CL, Levy A, Mercier O, Ngo C, Honoré C, Cesne AL, Mir O. Watson S, et al. Among authors: henon c. Cancer Med. 2023 Feb;12(3):3160-3166. doi: 10.1002/cam4.5147. Epub 2022 Aug 15. Cancer Med. 2023. PMID: 35971325 Free PMC article.
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Assi T, Ngo C, Faron M, Verret B, Lévy A, Honoré C, Hénon C, Le Péchoux C, Bahleda R, Le Cesne A. Assi T, et al. Among authors: henon c. Curr Treat Options Oncol. 2023 Nov;24(11):1598-1613. doi: 10.1007/s11864-023-01139-3. Epub 2023 Oct 16. Curr Treat Options Oncol. 2023. PMID: 37843627 Review.
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
Ibrahim R, Assi T, Khoury R, Ngo C, Faron M, Verret B, Lévy A, Honoré C, Hénon C, Le Péchoux C, Bahleda R, Le Cesne A. Ibrahim R, et al. Among authors: henon c. Cancer Treat Rev. 2024 Feb;123:102675. doi: 10.1016/j.ctrv.2023.102675. Epub 2023 Dec 25. Cancer Treat Rev. 2024. PMID: 38159438 Review.
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B. Hendriks LEL, et al. Among authors: henon c. Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 Jun 13. Eur J Cancer. 2019. PMID: 31203193
Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions.
Vibert J, Saulnier O, Collin C, Petit F, Borgman KJE, Vigneau J, Gautier M, Zaidi S, Pierron G, Watson S, Gruel N, Hénon C, Postel-Vinay S, Deloger M, Raynal V, Baulande S, Laud-Duval K, Hill V, Grossetête S, Dingli F, Loew D, Torrejon J, Ayrault O, Orth MF, Grünewald TGP, Surdez D, Coulon A, Waterfall JJ, Delattre O. Vibert J, et al. Among authors: henon c. Mol Cell. 2022 Jul 7;82(13):2458-2471.e9. doi: 10.1016/j.molcel.2022.04.019. Epub 2022 May 11. Mol Cell. 2022. PMID: 35550257 Free article.
Antibody drug conjugates in older patients: State of the art.
Rached L, Geraud A, Frelaut M, Ap Thomas Z, Goldschmidt V, Beraud-Chaulet G, Nagera-Lazarovici C, Danlos FX, Henon C, Parisi C, Gazzah A, Bahleda R, Postel Vinay S, Smolenschi C, Hollebecque A, Michot JM, Ribrag V, Loriot Y, Champiat S, Ouali K, Massard C, Ponce Aix S, Bringuier M, Baldini C. Rached L, et al. Among authors: henon c. Crit Rev Oncol Hematol. 2024 Jan;193:104212. doi: 10.1016/j.critrevonc.2023.104212. Epub 2023 Nov 24. Crit Rev Oncol Hematol. 2024. PMID: 38007063 Review.
24 results